**Pneumococcal Vaccine Timing**

**Age 65+ Years: All**

**Age 19-64 Years: Only if High-Risk**

### A. Unknown or No Prior Doses of PCV13 or PPSV23

<table>
<thead>
<tr>
<th>Option A1</th>
<th>Option A2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PCV20</strong> (Prevnar 20*) (PPSV23 not needed)</td>
<td><strong>PCV15</strong> (Vaxneuvance*)</td>
</tr>
</tbody>
</table>

≥1 year interval if:
- healthy 65+, or 19+ with other risks
- Consider ≥8 week interval if:
  - 19+ at highest-risk

**PPSV23** Pneumovax®

### B. Previously Received PPSV23

≥1 year since PPSV23

<table>
<thead>
<tr>
<th>OR</th>
<th>≥1 year interval if:</th>
</tr>
</thead>
</table>
| **PCV20** (Prevnar 20*) | healthy 65+, or 19+ with other risks
| **PCV15** (Vaxneuvance*) |

### C. Previously Received PCV13†

≥1 year since PCV13

<table>
<thead>
<tr>
<th>OR</th>
<th>≥1 year interval if:</th>
</tr>
</thead>
</table>
| **PCV20** (Prevnar 20*) | healthy 65+, or 19+ with other risks
| **PPSV23** (Pneumovax®) |

### D. Previously Completed Series of PCV13 and PPSV23 in Any Order†

≥5 years since PCV13 or PPSV23

<table>
<thead>
<tr>
<th>OR</th>
<th>≥1 year interval if:</th>
</tr>
</thead>
</table>
| **PCV20** (Prevnar 20*) | healthy 65+, or 19+ with other risks
| **PPSV23** (Pneumovax®) |

---

**Immunocompromising conditions, CSF leak or cochlear implant**

In Option A2, consider a minimum interval of 8 weeks between PCV15 and PPSV23 for these conditions:

- Asplenia, congenital or acquired
- CSF leak
- Cochlear implant
- Chronic renal failure
- Nephrotic syndrome
- Sickle cell disease or other hemoglobinopathies
- HIV infection
- Immunodeficiency, congenital or acquired
- Iatrogenic immunosuppression
- Solid organ transplant
- Generalized malignancy
- Leukemia
- Lymphoma
- Hodgkin disease
- Multiple myeloma

**Other risk factors**

In Option A2, minimum interval of 1 year between PCV15 and PPSV23 for these conditions:

- Alcoholism
- Cigarette smoking
- Diabetes mellitus
- Chronic heart disease
- Chronic liver disease
- Chronic lung disease

†Additional guidance from CDC at [Pneumococcal Vaccine Timing for Adults](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm)

For further details, see: [www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm)

California Department of Public Health, Immunization Branch [www.EZIZ.org](http://www.EZIZ.org)

IMM-1152 VFA (1/2024)